ArticleThe Journal of rheumatology2007
Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus.
Article in The Journal of rheumatology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Association between MPO-463G > A polymorphism and chronic kidney disease: a meta-analysis.Renal failure · 2018Pooled it
- Ameliorative Effect of Banana Lectin in TNBS-Induced Colitis in C57BL/6 Mice Relies on the Promotion of Antioxidative Mechanisms in the Colon.Biomolecules · 2025Article
- Genetic history of Cambridgeshire before and after the Black Death.Science advances · 2024Article
- The Enzymatic and Non-Enzymatic Function of Myeloperoxidase (MPO) in Inflammatory Communication.Antioxidants (Basel, Switzerland) · 2021Review
- Unexpected combination: DiGeorge syndrome and myeloperoxidase deficiency.BMJ case reports · 2020Article
- Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis.The Journal of biological chemistry · 2018Article
- Immunohistochemical Expression of Myeloperoxidase in Placental Samples of Systematic Lupus Erythematosus Pregnancies.Journal of family & reproductive health · 2016Article
- Koumine Attenuates Lipopolysaccaride-Stimulated Inflammation in RAW264.7 Macrophages, Coincidentally Associated with Inhibition of NF-κB, ERK and p38 Pathways.International journal of molecular sciences · 2016Article
- I too, am America: a review of research on systemic lupus erythematosus in African-Americans.Lupus science & medicine · 2016Review
- Role of Myeloperoxidase in Patients with Chronic Kidney Disease.Oxidative medicine and cellular longevity · 2016Review
- Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase.Journal of immunology research · 2016Review
- Systemic lupus erythematosus diagnostics in the 'omics' era.International journal of clinical rheumatology · 2013Article
- Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis.Clinical & developmental immunology · 2012Review
- Neutrophils in the pathogenesis and manifestations of SLE.Nature reviews. Rheumatology · 2011Review
- Mechanisms of tissue injury in lupus nephritis.Arthritis research & therapy · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveMyeloperoxidase (MPO) is an enzyme expressed in neutrophils that is involved in tissue damage in inflammatory renal diseases. A functional G to A single-nucleotide polymorphism (SNP) is present at position -463 of the MPO promoter region and is associated with altered MPO expression. We hypothesized that the G-463A MPO SNP is a risk factor for developing lupus nephritis (LN) due to its potential influence on the inflammatory response.
methodsDNA from 229 patients with SLE and 277 controls from the Carolina Lupus cohort, 58 African American patients from the Sea Island Lupus Cohort, and 51 African American patients from the Lupus Multiplex Registry and Repository were genotyped by PCR. A linear regression model was used to examine relationships between the MPO genotype, case/control status, demographic characteristics, and LN.
resultsThere was no association of MPO genotype with systemic lupus erythematosus (SLE). However, the odds of developing LN were significantly higher among those with an A allele, compared to those without, in African American cases of all 3 cohorts. When the likelihood of developing LN was compared across MPO genotypes, the risk of developing LN was significantly higher among cases with a GA genotype versus GG (OR 2.11, 95% CI 1.12 to 3.97) and even higher with AA versus GG (OR 3.52, 95% CI 1.41 to 8.77).
conclusionWhile the G-463A MPO SNP is not a risk factor for developing SLE, the low expressing A allele is a significant risk factor for developing LN that is gene dosage-dependent in African Americans.
Indexed as
Identifiers
17896805PMC2798120W2169344231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.